AACR 2022: Advancing the Development of CD16A-Based Bispecific Antibodies in Humanized CD16A Mouse Models

AACR 2022: Advancing the Development of CD16A-Based Bispecific Antibodies in Humanized CD16A Mouse Models

Conclusions

Human CD16A expression was confirmed in homozygous B-hCD16A mice by RT-PCR and flow cytometry. Similar proportions of splenic immune cells were observed between humanized B-hCD16A mice and wild-type mice. CD16A-based bispecific antibodies usually binds to CD16A on NK cells, whereas the other arm of the antibody binds to a tumor antigen on cancer cells. Initial in vivo efficacy evaluation indicated that anti-human CD16A-based antibodies controlled MC38 tumor growth in humanized B-hCD16A mice. These data suggest that the B-hCD16A mouse model is an effective tool for future in vivo efficacy evaluation of therapeutic CD16A-based bispecific antibodies prior to clinical development.

Share:

    Please fill out the form below to request a download of this poster

    [posterfiledownload]